Pfizer’s Paxlovid, a combination of Nirmatrelvir and Ritonavir, is currently approved by the FDA for emergency use in the treatment of mild to moderate COVID-19 in certain adult and child patients, but it is also a potent CYP3A4 inhibitor, which could lead to drug interactions. This evidence concerns the gene CYP3A4 and COVID-19.